HERA OX40L
/ Apogenix
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 19, 2019
Publication in human vaccines & immunotherapeutics illustrates the advantages of hexavalent CD40 agonists in targeting CD40 in immuno-oncology
(PharmiWeb)
- "Apogenix...announced today that a new publication in Human Vaccines & Immunotherapeutics highlights the advantages of hexavalent CD40 agonists, such as HERA-CD40L, in the targeting of CD40 in immuno-oncology...The review reveals that anti-CD40 antibodies do not achieve the appropriate clustering capacity required for effective signaling into the target cell because of their bivalent nature."
Review
1 to 1
Of
1
Go to page
1